Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics source : Www.halozyme.com save search
Halozyme Reports Second Quarter 2021 Results
Published: 2021-08-09 (Crawled : 20:00) - halozyme.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.02%
H: 0.38%
C: 0.15%
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 14.02%
H: 0.17%
C: -10.56%
results report
Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference
Published: 2021-07-30 (Crawled : 12:00) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 0.39%
H: 0.0%
C: 0.0%
growth conference
Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call
Published: 2021-07-27 (Crawled : 20:00) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 0.61%
H: 1.76%
C: 0.53%
financial results results conference
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Published: 2021-07-12 (Crawled : 12:15) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 1.09%
H: 0.72%
C: -0.35%
fda fda approval approval
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-01 (Crawled : 21:00) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 0.05%
H: 0.7%
C: -5.31%
presentation therapy collaboration
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
Published: 2021-05-21 (Crawled : 14:00) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 1.45%
H: 0.28%
C: -2.54%
positive chmp
Halozyme Reports First Quarter 2021 Results
Published: 2021-05-10 (Crawled : 20:00) - halozyme.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.22%
H: 0.13%
C: -1.04%
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: -8.68%
H: 6.89%
C: 1.38%
results report
Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference
Published: 2021-04-29 (Crawled : 21:00) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: -0.29%
H: 0.68%
C: -2.37%
conference health
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call
Published: 2021-04-20 (Crawled : 20:00) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: -0.26%
H: 4.84%
C: 4.56%
financial results results conference
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
Published: 2021-02-23 (Crawled : 21:12) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 2.25%
H: 16.84%
C: 6.59%
offering
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Published: 2020-11-23 (Crawled : 09:22) - halozyme.com
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 2.36%
H: 0.87%
C: -0.89%
license collaboration therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.